Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
April 11, 2024 08:05 ET
|
Tevogen Bio Inc
Tevogen’s Chief Scientific Officer explains the company’s oncology pipeline strategy as it relates to harnessing Cytotoxic T Lymphocytes to target cancers.
Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting
April 09, 2024 16:00 ET
|
Mural Oncology, Inc.
Mural Oncology, a clinical-stage immuno-oncology company, shared pre-clinical data from its Interleukin-18 (IL-18) and IL-12 programs at AACR today.
Aegion Announces Acquisition of Toncco
March 27, 2024 11:00 ET
|
Aegion Corp
Aegion Corporation today announced the acquisition of Toncco, an underground utilities company based in Ogden, Utah.
Midland confirme de hautes teneurs en lithium jusqu’à 3,6 % Li₂O sur des pegmatites à spodumène additionnelles sur Galinée
January 16, 2024 07:30 ET
|
Exploration Midland Inc
MONTRÉAL, 16 janv. 2024 (GLOBE NEWSWIRE) -- Exploration Midland inc. (« Midland ») (TSX-V: MD) a le plaisir de livrer de nouveaux résultats d’analyses ainsi qu’une mise à jour sur les travaux à...
Midland Confirms High-Grade Lithium Up to 3.6% Li₂O on Additional Spodumene-Bearing Pegmatites on Galinée Project
January 16, 2024 07:30 ET
|
Midland Exploration Inc.
MONTREAL, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Midland Exploration Inc. (“Midland”) (TSX-V: MD) is pleased to provide new assay results and upcoming work following the identification of a series of...
Boehringer expands production site in Greece for new medicine
January 11, 2024 10:15 ET
|
Boehringer Ingelheim
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, today announced a further expansion and upgrade of its plant in Koropi, Greece. With an investment of EUR 120 million, the...
Mural Oncology Announces Enhancements to Late-Stage Clinical Trials
January 08, 2024 07:00 ET
|
Mural Oncology, Inc.
Strategic changes to ARTISTRY-6 and ARTISTRY-7, both potentially registrational trials of nemvaleukin, are intended to result in more clinically meaningful dataMural intends to nominate development...
EVerZom : Ambition thérapeutique dans les biothérapies à base d’exosomes
December 13, 2023 05:07 ET
|
Everzom
EVerZom : Ambition thérapeutique dans les biothérapies à base d’exosomes Lauréat de l’EIC Accelerator pour sa plateforme d’innovation technologique, EVerZom dévoile son pipeline propriétaire de...
EVerZom: Therapeutic Ambition in Exosome Biotherapies
December 13, 2023 05:07 ET
|
Everzom
EVerZom: Therapeutic Ambition in Exosome Biotherapies EVerZom, winner of the EIC Accelerator for its breakthrough technology platform, presents its proprietary pipeline of exosome-based...
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
November 03, 2023 07:00 ET
|
AC Immune SA
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update Results from amyloid plaque reduction analysis (Abeta-PET) after 6 months of treatment with ACI-24.060 in ABATE...